Home » Stocks » EVAX

Evaxion Biotech A/S (EVAX)

Evaxion Biotech will go public soon. The estimated IPO date is February 4, 2021.
Stock Price: $10.00 - $12.00
Current IPO price range
Market Cap 208.44M
Revenue (ttm) n/a
Net Income (ttm) -14.27M
Shares Out 18.95M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a


Hide News
GlobeNewswire - 2 weeks ago

COPENHAGEN, Denmark, Jan. 08, 2021 -- Evaxion Biotech A/S (the “Company” or “Evaxion”), a clinical-stage biotechnology company...

NASDAQ - 2 weeks ago

Evaxion Biotech, a Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies, filed on Friday with the SEC to raise up to $35 million in an initial public offering.

SEC - 2 weeks ago

Evaxion Biotech A/S has filed to go public with an IPO on the NASDAQ.

Precision Vaccinations - 1 month ago

Copenhagen-based Evaxion Biotech announced the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, combined with checkpoint inhibitors in patients...

About EVAX

Evaxion Biotech is a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immun... [Read more...]

IPO Date
Feb 4, 2021
Lars Staal Wegner, MD
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements